Article Text

Download PDFPDF

Controlled and extended release metoprolol reduced death, hospital admissions, and symptoms in chronic heart failure

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In patients with symptomatic chronic heart failure, do controlled and extended release metoprolol succinate (a β-blocker) reduce mortality, hospital admissions, and symptoms?


Randomised (allocation concealed*), blinded (outcome assessor, {patients, and clinicians}),* placebo controlled trial with a mean follow up of 1 year.


313 investigational sites in the US and 13 European countries.


3991 patients (mean age 64 y, 78% men) who had had symptomatic heart failure (New York Heart Association [NYHA] class II to IV) for ≥3 months, a decreased ejection fraction (≤ 0.40), and a resting heart rate ≥68 beats/minute and had received optimal treatment for ≥2 weeks before randomisation. Exclusion criteria included acute myocardial infarction or unstable angina pectoris ≤ 28 …

View Full Text